ROBOSENSE
13.9.2022 17:01:40 CEST | Business Wire | Press release
RoboSense, a world-leading provider of Smart LiDAR Sensor Systems launched upgraded 128-beam LiDAR, RS-Ruby Plus, designed for autonomous driving commercial operation, and it debuted at CES2022. Nowadays, it obtained a large number of orders from multiple autonomous vehicle companies worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005763/en/
RS-Ruby Plus (Photo: Business Wire)
Breaking through the limitations of the previous generation RS-Ruby，the RS-Ruby Plus adopts a new modular architecture design, which reduces its size and weight by 50% compared with the previous generation, and reduces power consumption to 30W, which is 33% lower than RS-Ruby. In the past two years, RS-Ruby has supported Momenta, IdriverPlus, DeepRoute.ai, AutoX, Mushroom Car Alliance and over thousands RoboTaxi fleets in pilot commercial operations with its stable and reliable operation performance.
Six Upgrades of RS-Ruby Plus：
1. Automotive-grade design for reliability as the reference
RoboSense developed a new architecture design for RS-Ruby Plus with reference to automotive-grade standards to ensure that the product passes tens of automotive-grade reliability tests including mechanical shock, random vibration, low temperature operation, high-pressure water impact and EMC.
Watch：RS-Ruby Plus passed dozens of reliability tests
2. Comprehensively improve the perception distance
RoboSense achieved a breakthrough in the detection range of 905nm LiDAR on the premise of ensured safety of human eyes. The product reached a super detection range of 240m @10% standard reflectivity (under 100,000 Lux sunlight environment) and the overall detection range performance improved by 20%.
In the high-performance mode, Ruby Plus can increase the horizontal angular resolution of 128 channels from 0.2° to 0.1° at 10Hz refresh rate, thus providing more point cloud information in the horizontal direction. Meanwhile, 104 channels 0.1° vertical resolution, including 32 channels ultra-long detection range. RS-Ruby Plus detects cars at 218 meters with 4 lines and 13 points.
Watch：RS-Ruby Plus point cloud in various scenarios
3. Detection capability of black-painted vehicles boosted
Empowered by the super detection range capability, RS-Ruby Plus greatly improving the detection and recognition capabilities of perception for black vehicles.
The road line detection capability of RS-Ruby Plus has been improved, it stably detects 85-90 meters, thus further improving the safety and user experience of autonomous vehicles when changing lanes and going up and down ramps.
4. Higher accuracy and finer imaging
Detection range accuracy improvement of RS-Ruby Plus
- Near-field area 0.4~3m, accuracy up to ±3cm (@100,000 Lux lighting environment)
- Far-field area 3~240m, accuracy up to ±2cm (@100,000 Lux lighting environment)
The higher accuracy of LiDAR, the more precise and clear the shape of small objects like stone piers, lampposts and traffic cones can be restored.
5. Comprehensive anti-interference
RS-Ruby Plus uses the latest laser encryption technology, RS-Ruby Plus effectively resists interference from other LiDARs and ambient light and sunlight (100,000 Lux lighting).
6. Automotive Ethernet, gPTP, PTP
RS-Ruby Plus has automotive Ethernet interface. The product supports both GPS synchronization and network synchronization (PTP and gPTP time synchronization) protocols, which greatly reduces data transmission delay and simplifies cable layout.
RoboSense will always employ more advanced technology innovations and feature ever superior performance to empower industry partners, support the comprehensive commercialization of autonomous driving.
Read More: RoboSense Upgraded 128-beam LiDAR RS-Ruby Plus
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005763/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom